These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19484933)

  • 1. [Mutant prevention concentrations of antibacterial agents to ocular pathogenic bacteria].
    Liang QF; Wang ZQ; Li R; Luo SY; Deng SJ; Sun XG
    Zhonghua Yan Ke Za Zhi; 2009 Jan; 45(1):61-5. PubMed ID: 19484933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The concentrations of fluoroquinolones in prevention of Staphylococcus epidermidis from mutant in ocular surface].
    Sun ST; Chen ZJ; Xu J; Tian XL
    Zhonghua Yan Ke Za Zhi; 2006 Nov; 42(11):989-91. PubMed ID: 17386136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mutant prevention concentrations of fluoroquinolones for Staphylococcus aureus].
    Cui JC; Liu YN; Wang R; Liang BB; Pei F; Zheng ZJ
    Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1863-6. PubMed ID: 15631794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
    Firsov AA; Smirnova MV; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
    J Antimicrob Chemother; 2006 Dec; 58(6):1185-92. PubMed ID: 17028094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa.
    Hansen GT; Zhao X; Drlica K; Blondeau JM
    Int J Antimicrob Agents; 2006 Feb; 27(2):120-4. PubMed ID: 16426820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative mutant prevention concentration and mechanism of resistance to veterinary fluoroquinolones in Staphylococcus pseudintermedius.
    Awji EG; Tassew DD; Lee JS; Lee SJ; Choi MJ; Reza MA; Rhee MH; Kim TH; Park SC
    Vet Dermatol; 2012 Aug; 23(4):376-80, e68-9. PubMed ID: 22409306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combined application of ciprofloxacin and tobramycin on mutant selective windows of ciprofloxacin against Pseudomonas aeruginosa].
    Liu MT; Sheng MY; Zhang Y; Li Y
    Zhonghua Yi Xue Za Zhi; 2011 May; 91(20):1427-31. PubMed ID: 21756818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion.
    Firsov AA; Smirnova MV; Strukova EN; Vostrov SN; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2008 Dec; 32(6):488-93. PubMed ID: 18790614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in-vitro efficacy of fluoroquinolones against Streptococcus pneumoniae recovered from bacterial keratitis as determined by E-test.
    Ramakrishnan R; Ramesh S; Bharathi MJ; Amuthan M; Viswanathan S
    Indian J Pathol Microbiol; 2010; 53(2):276-80. PubMed ID: 20551532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of nemonoxacin (TG-873870), a novel non-fluorinated quinolone, against clinical isolates of Staphylococcus aureus, enterococci and Streptococcus pneumoniae with various resistance phenotypes in Taiwan.
    Chen YH; Liu CY; Lu JJ; King CH; Hsueh PR
    J Antimicrob Chemother; 2009 Dec; 64(6):1226-9. PubMed ID: 19833635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mutant selection window in rabbits infected with Staphylococcus aureus.
    Cui J; Liu Y; Wang R; Tong W; Drlica K; Zhao X
    J Infect Dis; 2006 Dec; 194(11):1601-8. PubMed ID: 17083047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [In vitro antibacterial activity of 2 new quinolones: A 56619 (difloxacin) and A 56620. Comparison with pefloxacin, ofloxacin and ciprofloxacin].
    Soussy CJ; Deforges L; Le Van Thoi J; Duval J
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):759-67. PubMed ID: 3309811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant prevention concentration of ciprofloxacin and enrofloxacin against Escherichia coli, Salmonella Typhimurium and Pseudomonas aeruginosa.
    Pasquali F; Manfreda G
    Vet Microbiol; 2007 Jan; 119(2-4):304-10. PubMed ID: 16987619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant prevention concentration of nalidixic acid, ciprofloxacin, clinafloxacin, levofloxacin, norfloxacin, ofloxacin, sparfloxacin or trovafloxacin for Escherichia coli under different growth conditions.
    Linde HJ; Lehn N
    J Antimicrob Chemother; 2004 Feb; 53(2):252-7. PubMed ID: 14688048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa.
    Rhee MK; Kowalski RP; Romanowski EG; Mah FS; Ritterband DC; Gordon YJ
    Am J Ophthalmol; 2004 Aug; 138(2):226-30. PubMed ID: 15289131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration.
    Olofsson SK; Marcusson LL; Komp Lindgren P; Hughes D; Cars O
    J Antimicrob Chemother; 2006 Jun; 57(6):1116-21. PubMed ID: 16624874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Susceptibility of 570 Pseudomonas aeruginosa strains to 11 antimicrobial agents and the mechanism of its resistance to fluoroquinolones].
    Lei YC; Wang HB; Sun ZY; Shen ZY
    Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):403-7. PubMed ID: 12820918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach.
    Blondeau JM
    Vet Dermatol; 2009 Oct; 20(5-6):383-96. PubMed ID: 20178475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing.
    Zinner SH; Lubenko IY; Gilbert D; Simmons K; Zhao X; Drlica K; Firsov AA
    J Antimicrob Chemother; 2003 Oct; 52(4):616-22. PubMed ID: 12951352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of levofloxacin against characterized ciprofloxacin-resistant Streptococcus pneumoniae.
    Lister PD
    Postgrad Med; 2008 Sep; 120(3 Suppl 1):46-52. PubMed ID: 18931471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.